Increased teicoplanin doses are associated with improved serum levels but not drug toxicity.
OBJECTIVE: Teicoplanin is widely used for the treatment of severe gram-positive infection, aiming to achieve trough serum levels of 20-60 mg/L for patients with severe infection. A standard 400 mg daily dose is frequently associated with sub-therapeutic levels, and we have therefore changed our rout...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2014
|